Non-selective beta-blockers

PreclinicalSmall molecule

Non-selective beta-blockers is one of 88 small molecule programs targeting Liver Transplant. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Liver TransplantActive, not recruiting

Portal Vein ThrombosisActive, not recruiting

CirrhosisActive, not recruiting

Liver TransplantPreclinical

Active, not recruiting

Portal Vein ThrombosisPreclinical

Active, not recruiting

CirrhosisPreclinical

Active, not recruiting

Competition

Competitive Landscape

353 competitors in Liver Transplant

#DrugCompanyPhaseTrials

Cysteine Hydrochloride

Novartis

Preclinical

3 2

Vemlidy

Gilead

Preclinical

3 3

Octreotide

Johnson & Johnson

Preclinical

2 4

Beyfortus

BeiGene

Preclinical

1 5

Prostigmin

Merck & Co.

Preclinical

1 6

Myfortic

Novartis

Preclinical

1 7

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Preclinical

4 8

Myfortic

Novartis

Preclinical

6 9

Cyklokapron

AAmring

Preclinical

2 10

Tyvyt

Innovent Biologics (Suzhou) Co. Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

PreclinicalNot yet recruiting

Gastric Varices

NCT07168395

Q4 2029

N/ARecruiting

Liver Transplant

NCT07111221

Clinical

Trials by Indication[1]

Cirrhosis1 trial

Effect of Non-Selective Beta-Blockers on Outcomes in Cirrhosis Patients After Hospitalization: A Retrospective Cohort Using Target Trial Design

Active, not recruiting·SSamsung Medical Center··NCT06977685·7,725 enrolled

Portal vein thrombosis1 trial

TIPS vs Endoscopic Therapy for Variceal Rebleeding in Cirrhotic Patients With Portal Vein Thrombosis

Unknown status·—·N/A·NCT02485184·120 enrolled

Liver Transplant1 trial

Portal Inflow Modulation Prior to Liver Transplantation in Patients With Increased Risk of Intraoperative Blood Loss

Recruiting·MMedical University of Warsaw·N/A·NCT07111221·104 enrolled

Gastric Varices1 trial

Pre-emptive RTO for An Early Detected Gastric Varices in CT/MR Angiogram Trial (PRADA Trial)

Not yet recruiting·UUniversity of California, Los Angeles·Preclinical·NCT07168395·68 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Non-selective beta-blockers. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Non-selective beta-blockers compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Non-selective beta-blockers. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of California, Los Angeles company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: UUniversity of California, Los Angeles

Non-selective beta-blockers

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Q4 2029

Trials by Indication[1]

Cirrhosis1 trial

Portal vein thrombosis1 trial

Liver Transplant1 trial

Gastric Varices1 trial

References

Drug Info

Quick Facts

Related News